A Comprehensive Microarray-Based DNA Methylation Study of 367 Hematological Neoplasms

Background Alterations in the DNA methylation pattern are a hallmark of leukemias and lymphomas. However, most epigenetic studies in hematologic neoplasms (HNs) have focused either on the analysis of few candidate genes or many genes and few HN entities, and comprehensive studies are required. Methodology/Principal Findings Here, we report for the first time a microarray-based DNA methylation study of 767 genes in 367 HNs diagnosed with 16 of the most representative B-cell (n = 203), T-cell (n = 30), and myeloid (n = 134) neoplasias, as well as 37 samples from different cell types of the hematopoietic system. Using appropriate controls of B-, T-, or myeloid cellular origin, we identified a total of 220 genes hypermethylated in at least one HN entity. In general, promoter hypermethylation was more frequent in lymphoid malignancies than in myeloid malignancies, being germinal center mature B-cell lymphomas as well as B and T precursor lymphoid neoplasias those entities with highest frequency of gene-associated DNA hypermethylation. We also observed a significant correlation between the number of hypermethylated and hypomethylated genes in several mature B-cell neoplasias, but not in precursor B- and T-cell leukemias. Most of the genes becoming hypermethylated contained promoters with high CpG content, and a significant fraction of them are targets of the polycomb repressor complex. Interestingly, T-cell prolymphocytic leukemias show low levels of DNA hypermethylation and a comparatively large number of hypomethylated genes, many of them showing an increased gene expression. Conclusions/Significance We have characterized the DNA methylation profile of a wide range of different HNs entities. As well as identifying genes showing aberrant DNA methylation in certain HN subtypes, we also detected six genes—DBC1, DIO3, FZD9, HS3ST2, MOS, and MYOD1—that were significantly hypermethylated in B-cell, T-cell, and myeloid malignancies. These might therefore play an important role in the development of different HNs.

[1]  Lucy Skrabanek,et al.  Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features. , 2009, Blood.

[2]  F. Prósper,et al.  Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. , 2007, Blood.

[3]  P. Meltzer,et al.  Large-scale profiling of archival lymph nodes reveals pervasive remodeling of the follicular lymphoma methylome. , 2009, Cancer research.

[4]  F. Prósper,et al.  Downregulation of DBC1 expression in acute lymphoblastic leukaemia is mediated by aberrant methylation of its promoter , 2006, British journal of haematology.

[5]  G. Garcia-Manero.  Demethylating agents in myeloid malignancies , 2008, Current opinion in oncology.

[6]  D. Phillips,et al.  Interleukin 1 receptor antagonist gene polymorphism and risk of lung cancer: a possible interaction with polymorphisms in the interleukin 1 beta gene. , 2005, Lung cancer.

[7]  I. Burney,et al.  Combined Polymorphism Analysis of Glutathione S-transferase M1/G1 and Interleukin-1B (IL-1B)/Interleukin 1-Receptor Antagonist (IL-1RN) and Gastric Cancer Risk in an Omani Arab Population , 2009, Journal of clinical gastroenterology.

[8]  B. Chait,et al.  Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement , 2003, Nature Immunology.

[9]  R. Spang,et al.  New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. , 2009, Blood.

[10]  C. Hother,et al.  Frequent hypermethylation of DBC1 in malignant lymphoproliferative neoplasms , 2008, Modern Pathology.

[11]  M. Fraga,et al.  The Polycomb group protein EZH2 directly controls DNA methylation , 2007, Nature.

[12]  T. Wolfsberg,et al.  DNA methylation profiles in diffuse large B-cell lymphoma and their relationship to gene expression status , 2008, Leukemia.

[13]  Matthias Burger,et al.  Distinction of acute lymphoblastic leukemia from acute myeloid leukemia through microarray-based DNA methylation analysis , 2005, Annals of Hematology.

[14]  E. Lander,et al.  The Mammalian Epigenome , 2007, Cell.

[15]  C. Meijer,et al.  Distinct expression patterns of polycomb oncoproteins and their binding partners during the germinal center reaction , 2004, European journal of immunology.

[16]  J. Herman,et al.  The fundamental role of epigenetics in hematopoietic malignancies. , 2006, Blood reviews.

[17]  U. Lehmann,et al.  Role of epigenetic changes in hematological malignancies , 2004, Annals of Hematology.

[18]  Emeka Nkenke,et al.  Gene expression polymorphisms of interleukins-1β, -4, -6, -8, -10, and tumor necrosis factors-α, -β: regression analysis of their effect upon oral squamous cell carcinoma , 2008, Journal of Cancer Research and Clinical Oncology.

[19]  Zohar Yakhini,et al.  Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer , 2007, Nature Genetics.

[20]  Randy D. Gascoyne,et al.  Array-based DNA methylation profiling in follicular lymphoma , 2009, Leukemia.

[21]  W. Lichtenegger,et al.  Monitoring of IL-10 in the serum of patients with advanced ovarian cancer: results from a prospective pilot-study. , 2009, Cytokine.

[22]  Vitaly L. Galinsky,et al.  Automatic registration of microarray images. II. Hexagonal grid , 2003, Bioinform..

[23]  C. Iacobuzio-Donahue,et al.  Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. , 2003, Cancer research.

[24]  Margaret Gardiner-Garden,et al.  Overexpression of the Cell Adhesion Molecules DDR1, Claudin 3, and Ep-CAM in Metaplastic Ovarian Epithelium and Ovarian Cancer , 2004, Clinical Cancer Research.

[25]  L. Dai,et al.  Inflammatory cytokine gene polymorphisms in gastric cancer cases' and controls' family members from Chinese areas at high cancer prevalence. , 2008, Cancer letters.

[26]  Valeria Santini,et al.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.

[27]  Ines Gockel,et al.  PDGFRalpha/beta expression correlates with the metastatic behavior of human colorectal cancer: a possible rationale for a molecular targeting strategy. , 2008, Oncology reports.

[28]  Michael B. Stadler,et al.  Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome , 2007, Nature Genetics.

[29]  N. Dolloff,et al.  Bone-metastatic potential of human prostate cancer cells correlates with Akt/PKB activation by α platelet-derived growth factor receptor , 2005, Oncogene.

[30]  Stephen B. Howell,et al.  Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers. , 2005, Human pathology.

[31]  J. Boultwood,et al.  Gene silencing by DNA methylation in haematological malignancies , 2007, British journal of haematology.

[32]  D Bentley,et al.  Highly parallel SNP genotyping. , 2003, Cold Spring Harbor symposia on quantitative biology.

[33]  Peter Gibbs,et al.  Cytosine methylation profiling of cancer cell lines , 2008, Proceedings of the National Academy of Sciences.

[34]  O. Baiocchi.  Hodgkin lymphoma and interleukin-10: shall we go down from the tip of the iceberg? , 2008, Leukemia & lymphoma.

[35]  Alexandra Pohl,et al.  Polymorphisms in interleukin 1 beta and interleukin 1 receptor antagonist associated with tumor recurrence in stage II colon cancer , 2009, Pharmacogenetics and genomics.

[36]  Wei Jiang,et al.  High-throughput DNA methylation profiling using universal bead arrays. , 2006, Genome research.

[37]  Mitsutoshi Nakamura,et al.  Prostate cancer antigen‐1 contributes to cell survival and invasion though discoidin receptor 1 in human prostate cancer , 2007, Cancer science.

[38]  M. Ehrlich,et al.  DNA methylation in cancer: too much, but also too little , 2002, Oncogene.

[39]  C W Caldwell,et al.  Differential DNA methylation patterns of small B-cell lymphoma subclasses with different clinical behavior , 2006, Leukemia.

[40]  Vitaly L. Galinsky,et al.  Automatic registration of microarray images. I. Rectangular grid , 2003, Bioinform..

[41]  P. Ongusaha,et al.  Discoidin domain receptor 1 receptor tyrosine kinase induces cyclooxygenase-2 and promotes chemoresistance through nuclear factor-kappaB pathway activation. , 2006, Cancer research.

[42]  David S Alberts,et al.  Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers. , 2005, Human pathology.

[43]  P. Laird,et al.  Epigenetic stem cell signature in cancer , 2007, Nature Genetics.

[44]  Ines Gockel,et al.  PDGFRα/β expression correlates with the metastatic behavior of human colorectal cancer: A possible rationale for a molecular targeting strategy , 2008 .

[45]  V. Madrid-Marina,et al.  Correlation Between IL-10 Gene Expression and HPV Infection in Cervical Cancer: A Mechanism for Immune Response Escape , 2008, Cancer investigation.

[46]  M. Tsao,et al.  Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma , 2007, British Journal of Cancer.

[47]  C. O'keefe,et al.  Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. , 2009, Blood.

[48]  Michael Rehli,et al.  Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia. , 2006, Cancer research.

[49]  Megan F. Cole,et al.  Control of Developmental Regulators by Polycomb in Human Embryonic Stem Cells , 2006, Cell.

[50]  Kenny Q. Ye,et al.  An Integrative Genomic and Epigenomic Approach for the Study of Transcriptional Regulation , 2008, PloS one.

[51]  Youping Deng,et al.  GeneVenn - A web application for comparing gene lists using Venn diagrams , 2007, Bioinformation.

[52]  Gerald L. Arthur,et al.  DNA hypermethylation accompanied by transcriptional repression in follicular lymphoma , 2009, Genes, chromosomes & cancer.

[53]  A. Ferguson-Smith,et al.  Deletions and epimutations affecting the human 14q32.2 imprinted region in individuals with paternal and maternal upd(14)-like phenotypes , 2008, Nature Genetics.

[54]  S. Hirohashi,et al.  Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers. , 2005, Human molecular genetics.

[55]  M. Toyota,et al.  Methylation profiling in acute myeloid leukemia. , 2001, Blood.

[56]  Jian Yu,et al.  Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis. , 2004, World journal of gastroenterology.

[57]  M. Dyer,et al.  The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. , 2000, Blood.

[58]  J. Taylor,et al.  The diagnostic significance of Myf-3 hypermethylation in malignant lymphoproliferative disorders , 2001, Leukemia.

[59]  Peter A. Jones,et al.  Epigenetics in cancer. , 2010, Carcinogenesis.

[60]  Y. Yagi,et al.  Methylation-associated silencing of heparan sulfate D-glucosaminyl 3-O-sulfotransferase-2 (3-OST-2) in human breast, colon, lung and pancreatic cancers , 2003, Oncogene.

[61]  R. Siebert,et al.  Combined single nucleotide polymorphism-based genomic mapping and global gene expression profiling identifies novel chromosomal imbalances, mechanisms and candidate genes important in the pathogenesis of T-cell prolymphocytic leukemia with inv(14)(q11q32) , 2007, Leukemia.

[62]  Kelly M. McGarvey,et al.  A stem cell–like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing , 2007, Nature Genetics.

[63]  J. Rogers,et al.  DNA methylation profiling of human chromosomes 6, 20 and 22 , 2006, Nature Genetics.

[64]  C. Meijer,et al.  Distinct BMI-1 and EZH2 Expression Patterns in Thymocytes and Mature T Cells Suggest a Role for Polycomb Genes in Human T Cell Differentiation , 2001, The Journal of Immunology.

[65]  J. Rowley.  The role of chromosome translocations in leukemogenesis. , 1999, Seminars in hematology.

[66]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.